Spironolactone

Generic Name
Spironolactone
Brand Names
Aldactazide, Aldactone, Carospir, Qaialdo
Drug Type
Small Molecule
Chemical Formula
C24H32O4S
CAS Number
52-01-7
Unique Ingredient Identifier
27O7W4T232
Background

Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...

Indication

Spironolactone is indicated for the treatment of the following conditions:

As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.

Associated Conditions
Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
Associated Therapies
Perioperative drug treatment, Maintenance therapy

Spironolactone for Pulmonary Arterial Hypertension

First Posted Date
2012-10-23
Last Posted Date
2024-12-19
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
70
Registration Number
NCT01712620
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mineralocorticoid Receptor Antagonists in End Stage Renal Disease

First Posted Date
2012-09-24
Last Posted Date
2019-08-06
Lead Sponsor
Wuerzburg University Hospital
Target Recruit Count
118
Registration Number
NCT01691053
Locations
🇩🇪

University Hospital Erlangen-Nürnberg, Erlangen, Germany

🇩🇪

University Hospital Frankfurt, Frankfurt, Germany

🇩🇪

University Hospital Wuerzburg, Wuerzburg, Germany

Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-09-19
Last Posted Date
2012-09-19
Lead Sponsor
Dialysis Outcomes Heart Failure Aldactone Study Group
Target Recruit Count
157
Registration Number
NCT01687699
Locations
🇯🇵

Shibukawa Clinic, Shizuoka, Japan

Resistant Hypertension Optimal Treatment

First Posted Date
2012-07-18
Last Posted Date
2013-06-07
Lead Sponsor
Instituto do Coracao
Target Recruit Count
2000
Registration Number
NCT01643434
Locations
🇧🇷

University of São Paulo General Hospital, São Paulo, Brazil

The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity

First Posted Date
2012-05-21
Last Posted Date
2021-09-09
Lead Sponsor
Odense University Hospital
Target Recruit Count
188
Registration Number
NCT01602861
Locations
🇩🇰

Odense University Hospital, Odense C, Denmark

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-05-15
Last Posted Date
2013-07-19
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
18
Registration Number
NCT01598740
Locations
🇺🇸

Orange Country Research Center, Tustin, California, United States

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

First Posted Date
2012-04-26
Last Posted Date
2022-10-07
Lead Sponsor
Montreal Heart Institute
Target Recruit Count
62
Registration Number
NCT01586442
Locations
🇨🇦

Montreal Heart Institute, Montreal, Quebec, Canada

Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis

First Posted Date
2012-03-13
Last Posted Date
2016-02-25
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Target Recruit Count
17
Registration Number
NCT01552044
Locations
🇫🇷

Hotel-Dieu of Paris, Paris, France

Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology

Phase 4
Conditions
Interventions
First Posted Date
2012-01-18
Last Posted Date
2012-01-18
Lead Sponsor
Clinical Hospital Merkur
Target Recruit Count
40
Registration Number
NCT01510795

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

First Posted Date
2011-12-08
Last Posted Date
2013-10-29
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT01488877
Locations
🇺🇸

Pfizer Investigational Site, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath